ImmunoMet Therapeutics

Executive Summary

ImmunoMet Therapeutics is a clinical-stage biotechnology company pioneering the development of small molecule therapies that exploit the unique metabolic vulnerabilities of cancer and fibrotic cells. Founded in 2015 and headquartered in Houston, Texas, the company's platform targets oxidative phosphorylation (OxPhos), a critical energy pathway for aberrant cell growth. Its lead asset, lixumistat (IM156), is an oral OxPhos inhibitor being evaluated in Phase 1 clinical trials for solid tumors and fibrotic diseases. By selectively disrupting the metabolic machinery of diseased cells while sparing normal tissues, lixumistat has the potential to offer a novel therapeutic approach with a favorable safety profile. The company's focus on metabolism positions it at the forefront of an emerging field in oncology and fibrosis, addressing significant unmet medical needs. With a strong intellectual property portfolio and a seasoned management team, ImmunoMet is poised to advance its pipeline and generate value for patients and stakeholders.

Upcoming Catalysts (preview)

• Q4 2026Phase 1 clinical data readout for lixumistat in solid tumors60% success
• Q1 2027Initiation of Phase 2 trial for lixumistat in fibrotic indications50% success
• Q2 2026Series C financing round to support pipeline expansion70% success